IPG Photonics Corporation research snapshot
IPGP AI stock analysis as of the August 3, 2026 data cutoff reads IPG Photonics as a cash-rich fiber laser technology leader in a deep cyclical drawdown. The stock closed at $85.06 on July 31, 2026, with a market capitalization near $3.61 billion, re-verified as $85.06 times 42.44 million shares outstanding per the StockAnalysis.com quote and statistics pages and the Q1 2026 condensed balance sheet, which lists 42,443,381 shares outstanding as of March 31, 2026. Revenue is recovering with TTM sales near $1.04 billion up about 9% and Q1 2026 sales up 17% year over year, but operating margins sit near zero, trailing twelve-month free cash flow turned negative at about -$13.9 million, and the stock trades below its 20, 50, 100, and 200-day moving averages after falling roughly 45% from the February 2026 high near $155.82. Two catalysts frame the near term: the Q2 2026 earnings report on August 4, 2026, with guidance of $260 million to $290 million in revenue and adjusted EPS of $0.25 to $0.55, and the announced Lumibird Medical acquisition for 300 million euros plus up to 50 million euros in earnout, expected to close in Q4 2026. This is informational research and not investment advice.
Current price
$85.06
Market cap
$3.61 billion
AI score
46 / 100
Rating
Cash-rich fiber laser leader in a deep cyclical drawdown
Trend status
Bearish: below the 5, 20, 50, 100, and 200-day moving averages after a sharp July selloff
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | IPG makes high-power fiber lasers and amplifiers used in cutting, welding, cleaning, marking, and advanced medical, semiconductor, and defense applications, with a vertically integrated model that historically delivered high margins. | Medium-high |
| Moat | The moat is vertical integration, fiber laser IP, and manufacturing scale, but Chinese competitors have narrowed the gap on standard low-to-mid power lasers and are pressuring pricing. | Medium |
| Management | CEO Dr. Mark Gitin is expanding Advanced Solutions, including the Lumibird Medical acquisition for 300 million euros, while managing tariff costs and cost discipline, but the post-founder strategy is still being proven. | Medium |
| Financial trend | TTM revenue recovered to about $1.04 billion up 9%, and Q1 2026 sales grew 17% year over year, but operating margin is near zero and TTM free cash flow turned negative at about -$13.9 million. | Medium-high |
| Valuation | At roughly 125x TTM GAAP EPS and 47x forward EPS, the stock prices in a strong earnings recovery; on sales the multiple is about 3.5x, and net cash of about $18.77 per share cushions part of the downside. | Low |
| Technical trend | IPGP closed at $85.06 on July 31, 2026, below its 5, 20, 50, 100, and 200-day moving averages with 14-day RSI near 35.6, deeply oversold stochastic readings, and -DI above +DI on ADX, a bearish configuration after a sharp July selloff. | Medium |
| Risk level | Key risks are Chinese laser competition, tariffs and retaliatory tariffs, negative free cash flow, the cash outlay and integration risk of the Lumibird Medical deal, cyclical industrial demand, and founder-succession execution. | Medium-high |
| AI confidence | Medium confidence for verified market data and filing-based figures that cross-check across StockAnalysis.com, Barchart, and the Q1 2026 earnings release. Lower confidence for the earnings trajectory given tariffs and the pre-earnings position ahead of August 4, 2026. | Medium data confidence |
| Investment certainty | Low certainty. IPGP is a cash-rich technology leader at a cyclical and technical low, but earnings visibility is poor, free cash flow is negative, and the stock could move sharply on the Q2 2026 report. | Low |
IPGP AI stock forecast
The IPGP AI stock forecast uses scenario math, not a price commitment. Starting from the FY2027 consensus adjusted EPS estimate of $2.31 and a 2-year horizon, the three-scenario framework produced a bearish area near $51 with no EPS growth and a 22x exit multiple, a base area near $89 with 10% annual EPS growth and a 32x multiple, and a bullish area near $156 with 30% annual EPS growth and a 40x multiple, before the balance sheet cushion. The near-term trigger is the Q2 2026 report on August 4, 2026.
$140 to $170
More likely if industrial demand recovers strongly, margins expand toward historical norms, the Lumibird Medical acquisition closes in Q4 2026 and lifts Advanced Solutions toward roughly 26% of sales, tariff pressure eases, and the market re-rates the stock toward a mid to high 30s forward multiple.
$80 to $110
More likely if Q2 2026 results near the $260 million to $290 million revenue and $0.25 to $0.55 adjusted EPS guidance, book-to-bill stays above one, competitive pressure persists, free cash flow slowly recovers, and the stock trades in a range between the 20-day and 200-day moving averages near $98 to $102.
$50 to $70
More likely if the industrial cycle extends its downturn, Chinese laser makers take additional share, tariffs persist, free cash flow stays negative, the Lumibird integration disappoints or closes late, and the multiple compresses toward historical forward norms of 20x to 25x.
IPGP AI technical analysis
IPGP AI technical analysis is bearish as of the August 3, 2026 data cutoff. The stock closed at $85.06 on July 31, 2026, below its 5-day average near $84.78, its 20-day near $97.84, its 50-day near $107.75, its 100-day near $111.70, and its 200-day near $101.94. Momentum is weak with 14-day RSI near 35.62, stochastic deeply oversold, and 14-day ADX near 28.30 with negative directional index above positive. Because this page does not fetch request-time market data and the Q2 2026 report lands on August 4, 2026, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $85.06 | StockAnalysis.com quote at the July 31, 2026 close, the latest verified close for the August 3, 2026 data cutoff. |
| Near support | $83 to $85 | The July 2026 consolidation area with recent intraday lows near $83.64, a short-term floor from the selloff. |
| Secondary support | $71 to $75 | The 52-week low of $71.35 and the psychological $75 zone, the deepest reference level in the current downtrend. |
| Near resistance | $97 to $102 | The 20-day moving average near $97.84 and the 200-day moving average near $101.94 form the first overhead zone. |
| Major resistance | $107 to $112 | The 50-day moving average near $107.75 and the 100-day near $111.70, the breakdown zone from the earlier 2026 recovery. |
| 50-day moving average | $107.75 | Barchart and StockAnalysis.com both reported the 50-day moving average near $107.75, well above the current price. |
| 200-day moving average | $101.94 | The 200-day moving average near $101.94 is above price, and a recovery back above it would be the first trend repair signal. |
| Momentum | RSI near 36, stochastic deeply oversold | 14-day RSI near 35.62 and 14-day stochastic near 12% to 18% signal weak momentum approaching oversold, while ADX near 28.30 with -DI near 32.05 above +DI near 14.78 confirms a downtrend. |
| Volume | 5-day average about 400,000; 20-day about 363,000 shares | Volume rose during the July decline, and the 5-day average near 400,000 is above the 20-day average near 363,000, showing selling participation. |
| Volatility | ATR about $6.4, historical volatility about 61% to 71% | 14-day ATR near $6.37 and 14-day historical volatility near 60.9% are elevated, and the August 4, 2026 earnings date adds event risk. |
| Invalidation | Close below $83.64, then recovery above $102 | A close below the July intraday low near $83.64 would open the $71 to $75 zone. A daily close back above the 200-day moving average near $102 would start to repair the bearish setup. |
IPGP AI trading strategy
The IPGP AI trading strategy is a rules-based research framework, not personalized advice. It combines verified balance-sheet evidence, technical confirmation, the August 4, 2026 earnings date, position sizing, and clear invalidation levels.
Look for IPGP to reclaim the 20-day moving average near $98 and the 200-day near $102 with above-average volume before treating the selloff as ending, with a push above $108 as the next trend-repair confirmation.
Avoid adding exposure right before the August 4, 2026 report because guidance has a wide adjusted EPS range of $0.25 to $0.55. A daily close below $83.64 should reduce confidence and trigger a stop.
If IPGP falls toward the $71 to $85 zone without a thesis break, compare the price reaction with the Q2 2026 report, book-to-bill, tariff commentary, and Lumibird closing timing before acting.
Do not buy the dip solely because the balance sheet is clean. The $796.6 million net cash near $18.77 per share is a cushion, but negative free cash flow means earnings quality still matters. Define maximum loss below the $71.35 52-week low.
Track quarterly revenue and margin trends, the Q2 2026 results and guidance, tariffs, free cash flow, Lumibird Medical integration, Chinese competitor pricing, book-to-bill, and cash balance.
Lower the rating if free cash flow stays negative, margins keep compressing, revenue growth fades, or cash balances decline sharply on the acquisition and buybacks.
Investment research summary
IPG sells high-power fiber lasers and amplifiers that cut, weld, clean, and mark materials in manufacturing, automotive, aerospace, medical, semiconductor, and defense industries, with customers paying for performance, reliability, and lower total cost of ownership.
The moat is vertical integration (making its own pump diodes, gain fibers, and optics), proprietary manufacturing processes, and over three decades of fiber laser expertise, reinforced by a global settlement of the TRUMPF patent litigation in May 2026. Chinese competitors have eroded the moat on standard low-to-mid power lasers.
The thesis can fail if Chinese laser makers keep improving quality while undercutting price, if industrial demand enters a prolonged downturn against IPG high fixed costs, if tariffs and retaliatory tariffs persist, if the Lumibird Medical deal closes late or integrates poorly, or if the post-founder leadership makes value-destroying capital allocation decisions.
Founder Valentin Gapontsev passed in 2022. CEO Dr. Mark Gitin has an operations and technology background and is steering the shift toward Advanced Solutions, including a 300 million euro binding offer for Lumibird Medical that is expected to close in Q4 2026. The capital allocation choice to spend cash on an acquisition while free cash flow is negative is the key open question.
Fiber lasers continue to displace legacy CO2 and solid-state lasers in materials processing, and newer applications in battery welding, EV manufacturing, handheld welding, cleaning, and medical lasers are expanding the addressable market, with the Lumibird deal adding about $1 billion of Advanced Solutions TAM.
At roughly 125x TTM GAAP earnings and 47x forward earnings, the stock embeds an expectation of earnings recovery. Net cash of about $796.6 million against a $3.61 billion market cap provides a partial floor, but the margin of safety depends on whether margins and free cash flow recover before tariffs and competition compress them further.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IPGP price | $85.06 close on July 31, 2026, after a $155.82 to $71.35 52-week range | StockAnalysis.com real-time quote | August 3, 2026 |
| Market capitalization | $3.61 billion, verified as $85.06 x 42.44 million shares with financial_rigor.py (0.00% deviation) | StockAnalysis.com statistics and financial_rigor.py market cap verification | August 3, 2026 |
| Shares outstanding | 42,443,381 shares as of March 31, 2026 | Q1 2026 earnings release condensed balance sheet | August 3, 2026 |
| TTM revenue | $1.04 billion, up 9.29% | StockAnalysis.com financials | August 3, 2026 |
| TTM net income and EPS | Net income $28.92 million with EPS $0.68 on the statistics page versus $0.69 on the financials page | StockAnalysis.com statistics and financials | August 3, 2026 |
| Q1 2026 results | Revenue $265.5 million up 17%, GAAP operating loss $7.7 million, net income $1.6 million, diluted EPS $0.04, adjusted EBITDA $35.2 million, adjusted EPS $0.29 | IPG Photonics Q1 2026 earnings release | August 3, 2026 |
| Q1 2026 sales by application | Industrial Solutions $227.6 million up 21%, Advanced Solutions $37.9 million down 5%, emerging growth products 53% of revenue | IPG Photonics Q1 2026 earnings release | August 3, 2026 |
| Q2 2026 guidance | Revenue $260 million to $290 million, adjusted gross margin 37% to 40%, adjusted operating expenses $92 million to $95 million, adjusted EPS $0.25 to $0.55, adjusted EBITDA $32 million to $48 million | IPG Photonics Q1 2026 earnings release | August 3, 2026 |
| Q2 2026 earnings date | Before the market opens on Tuesday, August 4, 2026 | IPG Photonics announcement, July 21, 2026 | August 3, 2026 |
| Lumibird Medical acquisition | Binding offer to acquire Lumibird Medical for 300 million euros cash-free, debt-free, plus up to 50 million euros in earnout tied to 2026 and 2027 metrics, funded with cash on hand, expected to close in Q4 2026 | IPG Photonics press release, July 16, 2026 | August 3, 2026 |
| Lumibird Medical profile | FY2025 revenue of 112.2 million euros and EBITDA of 24.1 million euros at a 21.5% margin under IFRS, with more than 450 employees and brands including Quantel Medical, Ellex, and Optotek Medical | IPG Photonics Lumibird Medical press release | August 3, 2026 |
| Cash and short-term investments | $812.91 million as of March 31, 2026, with cash of $480.76 million and short-term investments of $332.14 million, plus $70.57 million in long-term investments | Q1 2026 earnings release balance sheet and StockAnalysis.com | August 3, 2026 |
| Total debt and net cash | Total debt of $16.31 million and net cash of $796.59 million, or $18.77 per share | StockAnalysis.com statistics | August 3, 2026 |
| Enterprise value | $2.81 billion | StockAnalysis.com statistics | August 3, 2026 |
| Valuation math | 125.17x TTM PE, 47.07x forward PE, 3.47x sales, 1.71x book value, PEG 2.27, EV/EBITDA 39.66, earnings yield 0.80%, cross-checked with financial_rigor.py (PE 125.09x, PS 3.47x, PB 1.71x) | StockAnalysis.com statistics and financial_rigor.py | August 3, 2026 |
| Cash flow | TTM operating cash flow of $56.44 million, capital expenditures of -$70.29 million, free cash flow of -$13.86 million | StockAnalysis.com cash flow statement | August 3, 2026 |
| Margins | TTM gross margin 37.56%, operating margin 2.34% per the statistics page versus GAAP operating income of $3.54 million at a 0.34% margin per the financials page, and net margin 2.78% | StockAnalysis.com statistics and financials | August 3, 2026 |
| FY2021 to FY2025 revenue trend | FY2021 $1.461 billion, FY2022 $1.430 billion, FY2023 $1.287 billion, FY2024 $977.13 million, FY2025 $1.004 billion, with gross margin down from 47.67% in FY2021 to 38.00% in FY2025 | StockAnalysis.com financials | August 3, 2026 |
| 52-week range | $71.35 to $155.82 | StockAnalysis.com quote | August 3, 2026 |
| Analyst consensus | Buy with an average target of $131.93 across 9 analysts, median $125, low $92.5, and high $160, implying about 55% upside | StockAnalysis.com forecast | August 3, 2026 |
| Analyst rating mix, July 2026 | 4 Strong Buy, 2 Buy, 2 Hold, 1 Sell out of 9 analysts | StockAnalysis.com forecast recommendation trends | August 3, 2026 |
| Recent analyst target updates | Needham $110 to $120 on July 17, Stifel $125 on July 17, Roth MKM $149 to $151 on May 19, Citi $105 to $150 on May 7, Raymond James $180 to $160 on May 7 | StockAnalysis.com forecast | August 3, 2026 |
| FY2026 and FY2027 consensus estimates | FY2026 revenue $1.11 billion with adjusted EPS $1.62, FY2027 revenue $1.21 billion with adjusted EPS $2.31 | StockAnalysis.com forecast financial forecast | August 3, 2026 |
| Technical snapshot | 5-day average near $84.78, 20-day near $97.84, 50-day near $107.75, 100-day near $111.70, 200-day near $101.94, 14-day RSI near 35.62, 14-day ADX near 28.30 with -DI near 32.05 above +DI near 14.78, 14-day ATR near $6.37 | Barchart technical analysis | August 3, 2026 |
| Short interest | 3.15 million shares short, 7.43% of shares outstanding and 12.10% of float, 8.02 days to cover | StockAnalysis.com statistics | August 3, 2026 |
| TRUMPF patent litigation | IPG announced a global settlement with TRUMPF Laser- und Systemtechnik SE on May 5, 2026 to resolve and dismiss all patent litigation worldwide between the parties | IPG Photonics press release, May 5, 2026 | August 3, 2026 |
| Book-to-bill | Firmly above one in Q1 2026 per management, reflecting demand for laser solutions despite tariff uncertainty | IPG Photonics Q1 2026 earnings release | August 3, 2026 |
This IPGP AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the August 3, 2026 data cutoff, and they can be wrong, incomplete, or outdated after the August 4, 2026 earnings report, new tariff policy, competitive developments, or market moves.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
